Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Agenus, Inc. – Product Pipeline Review – H2 2011

VIEWS: 2 PAGES: 76

Agenus, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Agenus, Inc. - Product Pipeline Review - H2 2011” provides data on the Agenus, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Agenus, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Agenus, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Agenus, Inc. - Brief Agenus, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Agenus, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Agenus, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Agenus, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Agenus, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Agenus, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Agenus, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.

More Info
									        Agenus, Inc. – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01756CDB

                                                                                                 Publication Date: NOV 2011




Agenus, Inc. – Product Pipeline Review – H2 2011                                            GMDHC01756CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Agenus, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Agenus, Inc. Snapshot ............................................................................................................................................................................................. 6
      Agenus, Inc. Overview ....................................................................................................................................................................................... 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Agenus, Inc. – Research and Development Overview .............................................................................................................................................. 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Agenus, Inc. – Pipeline Review ................................................................................................................................................................................ 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      Agenus, Inc. – Pipeline Products Glance...........................................................................................................................................................10
      Agenus, Inc. Clinical Stage Pipeline Products ...................................................................................................................................................10
            Phase II Products/Combination Treatment Modalities .................................................................................................................................10
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................11
Agenus, Inc. – Drug Profiles ....................................................................................................................................................................................12
      HerpV ...............................................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      Nystatin .............................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      Prophage ..........................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
Agenus, Inc. – Pipeline Analysis ..............................................................................................................................................................................16
      Agenus, Inc. – Pipeline Products by Therapeutic Class .....................................................................................................................................16
      Agenus, Inc. - Pipeline Products By Target .......................................................................................................................................................17
      Agenus, Inc. – Pipeline Products by Route of Administration.............................................................................................................................18
      Agenus, Inc. – Pipeline Products by Molecule Type ..........................................................................................................................................19
Agenus, Inc. – Recent Pipeline Updates .................................................................................................................................................................20
Agenus, Inc. - Dormant Projects ..............................................................................................................................................................................24
Agenus, Inc. - Discontinued Pipeline Products.........................................................................................................................................................25
      Discontinued Pipeline Product Profiles ..............................................................................................................................................................25
            Aroplatin .....................................................................................................................................................................................................25
            ATRA-IV .....................................................................................................................................................................................................25
            AU-801 .......................................................................................................................................................................................................26
            HSPPC-70 ..................................................................................................................................................................................................26
            Zintevir........................................................................................................................................................................................................26
Agenus, Inc. – Company Statement ........................................................................................................................................................................27
Agenus, Inc. – Locations And Subsidiaries ..............................................................................................................................................................30
      Head Office .......................................................................................................................................................................................................30
      Other Locations & Subsidiaries .........................................................................................................................................................................30




Agenus, Inc. – Product Pipeline Review – H2 2011                                                                                                            GMDHC01756CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                 Page(2)
Agenus, Inc. – Product Pipeline Review



Recent Developments .............................................................................................................................................................................................31
           Sep 29, 2008: Antigenics Receives FDA Permission For The Export Of Oncophage To Russia .................................................................31
           Jul 27, 2010: Antigenics Announces Positive Phase I Trial Results Of AG-707 For Treatment Of Genital Herpes.......................................31
           Jun 27, 2011: Agenus’s Herpes Study Results Presented At BIO International Convention Show Robust Immune Response ....................32
           Sep 26, 2011: Agenus Announces Positive Phase I Study Results Of HerpV In Genital Herpes .................................................................33
           Oct 25, 2010: Antigenics Expands Phase II Trial In Glioma.........................................................................................................................34
           Oct 25, 2005: Antigenics Begins Phase I Trial Of Aroplatin In Solid Tumors And B-Cell Lymphoma ...........................................................34
           Nov 24, 2008: Antigenics Announces Final Data From Phase I Investigator-Sponsored Trial Of Oncophage Cancer Vaccine In Glioma ....35
           Nov 21, 2005: Antigenics Initiates Investigator-Sponsored Phase I/II Trial Of Its Oncophage Cancer Vaccine In Glioma ............................36
           May 20, 2010: Antigenics Presents Data On Oncophage Vaccine At International Conference On Brain Tumor Research And Therapy....36
           Oct 18, 2005: Antigenics Initiates Phase 1 Clinical Trial Of AG-707 Therapeutic Vaccine For Genital Herpes.............................................37
           May 18, 2011: Agenus To Present New Data From Prophage G-200 Phase II Recurrent Glioma Trial At ASCO 2011 Annual Meeting ......38
           Nov 16, 2006: Antigenics Presentes Preliminary Data From Phase I/II Investigator-Sponsored Trial Of Its Investigational Cancer Vaccine
           Oncophage At Immunotherapy Task Force Meeting At The Society Of Neuro-Oncology’s Annual Meeting ................................................38
           Nov 12, 1996: Clinical Results Reported On HIV Integrase Inhibitor ...........................................................................................................39
           Aug 12, 2009: Antigenics Begins Enrollment Of Patients In Its Phase II Trial Of Oncophage Cancer Vaccine In Newly Diagnosed Glioma 40
           Mar 12, 2009: Antigenics Receives European Orphan Drug Designation For Oncophage Cancer Vaccine In Brain Cancer .......................40
           Dec 09, 2003: Antigenics Reports Update On Cancer Vaccine Clinical Trials At American Society of Hematology (ASH) Meeting .............41
           Nov 09, 1999: Aronex Pharmaceuticals Receives Orphan Drug Designation For Mesothelioma Indication For Platar (now "Aroplatin")......41
           Apr 08, 2008: Antigenics Announces Approval Of Oncophage For The Treatment OF Intermediate-Risk Kidney Cancer in Russia ............42
           Jun 07, 2006: Antigenics Announces Results From In-Depth Analysis Of Phase III Data Of Oncophage In Kidney Cancer And Provides
           Regulatory Update ......................................................................................................................................................................................42
           Jun 07, 2005: Antigenics’ Oncophage Cancer Vaccine Receives European Orphan Drug Designation For Renal Cell Carcinoma .............43
           Jun 06, 2011: New Data From Phase II Brain Cancer Study With Prophage Series G-200 Shows Improved Overall Survival.....................44
           May 02, 2005: Nature Immunology Publication Supports Immunological Mechanism Of Action Of Antigenics’ Vaccines ............................45
           Jun 01, 2009: Antigenics Presents Positive Oncophage Interim Survival Data At ASCO .............................................................................46
Financial Deals Landscape......................................................................................................................................................................................47
     Agenus, Inc., Deals Summary ...........................................................................................................................................................................47
Agenus, Inc., Pharmaceuticals & Healthcare, Deal Details ......................................................................................................................................48
     Partnerships ......................................................................................................................................................................................................48
           Agenus Enters Into Research Agreement With Memorial Sloan-Kettering Cancer Center ...........................................................................48
     Licensing Agreements .......................................................................................................................................................................................50
           Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For
								
To top